Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

CK1D Development Update

Published: Tuesday, August 07, 2012
Last Updated: Tuesday, August 07, 2012
Bookmark and Share
Proteome Sciences has achieved further milestones in the development of inhibitors of the casein kinase 1 delta (CK1d) target in its Alzheimer's disease portfolio.

A second round of structure activity relationship (SAR) modelling of the most active and selective CK1d inhibitors has produced a marked improvement in activity and selectivity against the main anti-target.

Following successful in silico modelling and screening of CK1d a panel of over 600 candidate compounds were identified. To date, around half of these have been tested in an in vitro assay with a good percentage of those tested showing strong activity. After the first round of SAR two compounds PS110 and PS278 were shown to knock down levels of Tau phosphorylation in a recently published human neuronal cell line model over-expressing Tau protein, as measured using proprietary pTau 2.0 & 3.0 assays that are only available through PS Biomarker Services.

In the latest round of SAR analysis we have significantly improved the anti-Ck1d activity of both compounds and for PS278 also substantially improved its selectivity by over seven-fold against the main anti-target. Further profiling of the developed SAR compounds including in vitro and in vivo pharmacokinetic studies will be completed during the summer and evaluation of biological activity assessed in a whole organism model with results expected in the autumn.

"The extensive CK1D in vitro testing programme has been matched with innovative modelling software and has led to new areas of synthetic interest. Molecules from this programme are being tested and early data suggests greater potency and selectivity. Confirmation of these studies will allow selection of the molecules to enter the key in vivo studies in Q3/4 2012." Professor Bill Dawson, non-executive director of Proteome Sciences said, adding  "I am delighted to see the successful interaction between the biological modelling and informatics programmes. It is key to explore the chemical space effectively and quickly so that these interesting series may be rapidly exploited."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Thursday, September 22, 2016
Proteome Sciences Signs $2m Contract with Genting TauRx Diagnostic Centre
Contract to develop diagnostic panels to detect Alzheimer’s disease and monitor treatment efficacy.
Tuesday, September 30, 2014
Stroke Biomarker License to Randox
Stroke biomarker to develop and produce diagnostic tests that could increase by fivefold the number of patients treated for stroke.
Friday, April 06, 2012
Completion of Alzheimer’s Plasma Biomarker Study
The preliminary results demonstrate significant diagnostic and prognostic utilities.
Wednesday, April 04, 2012
Scientific News
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos